Pemvidutide

Pemvidutide, a glucagon-like peptide-1/glucagon dual receptor agonist, lowered liver fat content, markers of inflammation and body weight in patients with metabolic dysfunction-associated steatotic liver disease and obesity, research showed.

A slew of new medications currently in development may allow health care providers to go beyond glycemic management in the treatment of type 2 diabetes, according to a speaker.

About half of adults taking a novel peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity in nonalcoholic steatohepatitis lost 10% or more body weight at 24 weeks, according to a press release.